XML 52 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Collaboration Agreements (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 10 Months Ended
Aug. 03, 2020
USD ($)
Option
Aug. 31, 2021
Apr. 30, 2020
USD ($)
Jun. 30, 2019
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
May 01, 2024
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Development milestone payment         $ 0.0 $ 0.0  
Catalent Maryland, Inc. (Catalent)              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Annual fee payable, term       5 years      
Period for which annual fee is payable     5 years        
Term of manufacturing and supply agreement     5 years        
Minimum amount agreed to purchase in batches of drug product     $ 10.6        
Accrued payments on collaboration         4.0 4.0  
Prepaid assets related to upfront payments         5.3 5.3  
Payments made           2.0  
Catalent Maryland, Inc. (Catalent) | General and administrative              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Expenses on elimination of prepaid asset           5.3  
Expense on write off           11.3  
Expense on write off of aggregate payments           6.0  
Catalent Maryland, Inc. (Catalent) | Subsequent Events              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate payments on collaboration             $ 6.0
Amended and restated agreement with Penn              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Annual fee payable $ 5.0            
Quarterly fee payable $ 1.3            
Number of CNS indications | Option 8            
Upfront payments $ 1.0            
Upfront fee payable upon clinical candidate designation 0.5            
Upfront fee due $ 0.5            
Payment made on option exercise         1.5 3.0  
Amount payable per product candidate arising from the exploratory program for large CNS indications         39.0 39.0  
Sales milestone payments         55.0 55.0  
Amended and restated agreement with Penn | Minimum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaboration agreement, tiered transaction fee percent   1.00%          
Amended and restated agreement with Penn | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaboration agreement, tiered transaction fee percent   2.00%          
Amount payable per product candidate for rare, monogenic disorders         $ 16.5 $ 16.5